Financials data is unavailable for this security.
View more
Year on year Zhangzhou Pientzehuang Pharmaceutical Co Ltd grew revenues 15.69% from 8.69bn to 10.06bn while net income improved 13.15% from 2.47bn to 2.80bn.
| Gross margin | 43.91% |
|---|---|
| Net profit margin | 28.46% |
| Operating margin | 33.77% |
| Return on assets | 18.22% |
|---|---|
| Return on equity | 22.79% |
| Return on investment | 22.51% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Zhangzhou Pientzehuang Pharmaceutical Co Ltd fell by 1.33bn. However, the company earned 2.21bn from its operations for a Cash Flow Margin of 21.94%. In addition the company used 2.77bn on investing activities and also paid 769.30m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 23.24 |
|---|---|
| Tangible book value per share | 22.78 |
More ▼
Balance sheet in CNYView more
| Current ratio | 5.12 |
|---|---|
| Quick ratio | 3.64 |
| Total debt/total equity | 0.084 |
|---|---|
| Total debt/total capital | 0.0747 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 85.60% and 13.15%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 0.48% |
|---|---|
| Div growth rate (5 year) | 31.06% |
| Payout ratio (TTM) | 45.45% |
| EPS growth(5 years) | 19.60 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 9.02 |
More ▼
